{
    "2019-10-01": [
        [
            {
                "time": "2018-03-15",
                "original_text": "As Buyout Fever Grows, Alexion, Amarin and BioMarin Are Potential Targets",
                "features": {
                    "keywords": [
                        "buyout",
                        "Alexion",
                        "Amarin",
                        "BioMarin",
                        "targets"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Why the Earnings Surprise Streak Could Continue for Pfizer (PFE)",
                "features": {
                    "keywords": [
                        "earnings",
                        "surprise",
                        "streak",
                        "Pfizer"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "AstraZeneca/Merck's Lynparza Positive in Prostate Cancer Study",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Merck",
                        "Lynparza",
                        "prostate cancer",
                        "study"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-05",
                "original_text": "LabCentral gets state, private funds for new biomanufacturing lab space",
                "features": {
                    "keywords": [
                        "LabCentral",
                        "state funds",
                        "private funds",
                        "biomanufacturing",
                        "lab space"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}